Foundayo (orforglipron): the once-daily weight-loss tablet, explained

What is Foundayo?

Foundayo is the brand name for orforglipron, a once-daily oral medicine developed by Eli Lilly and Company for long-term weight management. It belongs to a class of drugs called GLP-1 receptor agonists — the same broad family as the better-known injections Mounjaro and Wegovy — but Foundayo is taken as a tablet rather than an injection.

What sets it apart from other GLP-1 medicines is chemistry. Most GLP-1 drugs are peptides, which the body digests easily; that is why they are usually injected, and why an oral peptide GLP-1 such as Rybelsus has to be taken under strict conditions to survive the stomach. Foundayo is a small-molecule (non-peptide) GLP-1 receptor agonist. Because it is a small molecule, it does not need those absorption-protecting rules. Lilly describes it as the only GLP-1 pill for weight loss that can be taken any time of day, without food or water restrictions.

Who makes it, and where did it come from?

Foundayo is made by Eli Lilly and Company. The molecule itself was originally discovered by Chugai Pharmaceutical Co., Ltd. of Japan, and licensed to Lilly in 2018. Lilly then took it through late-stage clinical trials and regulatory filing.

Because orforglipron is a small molecule, it can be manufactured by conventional chemical synthesis rather than the more complex fermentation and peptide synthesis that injectable GLP-1s require. In practice that means it can, in principle, be produced more cheaply and at far larger scale — which is why Lilly has committed to major new manufacturing capacity, including a $6 billion plant announced in Huntsville, Alabama, and further oral-medicines facilities in the Netherlands and China as part of a broader manufacturing investment programme. You can read more about the drug's origins and the science on our how Foundayo was developed page.

How does Foundayo work?

Foundayo activates the GLP-1 receptor, mimicking a natural gut hormone that the body releases after eating. Broadly, that does two things: it helps regulate appetite so people feel full sooner and eat less, and it supports better blood-sugar control. Over time, eating less alongside a reduced-calorie diet and more physical activity is what drives weight loss. It is intended as an adjunct to diet and exercise, not a replacement for them.

Foundayo compared with Rybelsus, an oral GLP-1 pill

A useful comparison is with Rybelsus (oral semaglutide), an earlier oral GLP-1 tablet. The practical difference matters for everyday life:

That flexibility is Foundayo's headline advantage as a pill: no timing to plan your day around, and no fasting window.

What did the trials show?

Foundayo's evidence comes mainly from Lilly's Phase 3 ATTAIN programme. The two headline trials each ran for 72 weeks and compared orforglipron against a placebo, both alongside a reduced-calorie diet and increased physical activity.

ATTAIN-1 — adults with obesity, without type 2 diabetes

ATTAIN-1 enrolled 3,127 adults with obesity (or overweight with weight-related health problems) who did not have type 2 diabetes, and was published in the New England Journal of Medicine. At the highest research dose, average weight loss at 72 weeks was 12.4% of body weight (about 12.4 kg, or 27.3 lb), compared with just 0.9% on placebo. Roughly 39.6% of people on the top dose lost at least 15% of their body weight, and about 59.6% lost at least 10%. The trial also reported improvements in cholesterol, triglycerides and blood pressure.

ATTAIN-2 — adults who also have type 2 diabetes

ATTAIN-2 studied more than 1,600 adults who had obesity or overweight plus type 2 diabetes, and was published in The Lancet. At the highest dose, average weight loss was 10.5% (about 22.9 lb) versus 2.2% on placebo, and blood-sugar control improved, with HbA1c falling by up to 1.8 percentage points. Slightly lower weight loss in people with type 2 diabetes is a pattern seen right across the GLP-1 class, not something unusual to Foundayo.

We summarise the strengths, the slow dose build-up and the reasoning behind it on our Foundayo dosage and titration page.

What are the side effects?

As with other GLP-1 medicines, the most common side effects in trials were gastrointestinal — nausea, constipation, diarrhoea and vomiting — and were mostly mild to moderate and related to dose. They were more common at higher doses, which is one reason the medicine is started low and increased gradually. Other reported effects included indigestion, abdominal pain, headache, bloating, fatigue and hair loss.

Foundayo's US labelling also carries more serious warnings, including a class warning about a possible risk of thyroid tumours, and it is not for people with a personal or family history of medullary thyroid carcinoma or the MEN 2 syndrome. These are matters for a prescriber to assess, and our Foundayo side effects page goes through them in more detail. This is general information and not a substitute for professional advice.

Can I get Foundayo in the UK?

Not at the moment, and it is important to be clear about why. Foundayo was approved by the US FDA on 1 April 2026, but a US approval does not permit sale in Britain. In the UK, a medicine must first be licensed by the MHRA (the Medicines and Healthcare products Regulatory Agency). As of mid-2026, orforglipron is under review but not yet approved in the UK.

Lilly has said it has submitted orforglipron for approval in more than 40 countries, including the UK, and plans to launch shortly after each clearance. The commonly cited expectation among UK pharmacy commentators is a possible UK licence around late 2026 to early 2027 — but that is an industry projection, not a date confirmed by Lilly or the MHRA. It could move.

NHS availability is a separate and later question. Even after an MHRA licence, the National Institute for Health and Care Excellence (NICE) would need to appraise whether the NHS should fund it, and — as with Mounjaro and Wegovy — any NHS access would likely be restricted to specific patient groups rather than open to all. A realistic NHS-funding decision is 2027 or later. Our Foundayo UK availability page tracks this in full.

Is Foundayo right for me?

This website cannot answer that, and neither can any advert. Foundayo is a prescription-only medicine designed for adults with obesity, or overweight with weight-related health conditions, as one part of a wider plan that includes diet and physical activity. It is not suitable for everyone, it has real side effects, and it interacts with other conditions and medicines. Whether it — or any weight-loss medicine — is appropriate for a particular person is a clinical judgement for a qualified prescriber after a proper assessment, not a decision to make from a web page. If you are thinking about weight-loss treatment, a good starting point is a conversation with your GP or pharmacist, or the NHS guidance below.

Where to read more

For trustworthy, non-commercial background, the NHS explains weight-loss medicines and obesity treatment at nhs.uk, and NICE publishes its guidance and appraisals at nice.org.uk. The MHRA's role and medicine safety information is on gov.uk. Around this site, you can read how Foundayo is dosed, its side effects and warnings, how it was developed, the latest on its UK availability, or browse common questions.

References

1. Eli Lilly and Company. "FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions". investor.lilly.com
2. Aronne LJ et al. "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist" (ATTAIN-1). New England Journal of Medicine. nejm.org
3. Eli Lilly and Company. "Lilly's oral GLP-1 orforglipron successful in third Phase 3 trial" (ATTAIN-2). investor.lilly.com
4. ATTAIN-2, The Lancet (published). thelancet.com
5. US Food and Drug Administration. Approval letter, NDA 220934. accessdata.fda.gov
6. NHS. Obesity — treatment and weight-loss medicines. nhs.uk
7. National Institute for Health and Care Excellence. nice.org.uk
8. Medicines and Healthcare products Regulatory Agency. gov.uk